Quantcast

Latest Heparin Stories

2008-10-14 09:00:00

DURHAM, N.C., Oct. 14 /PRNewswire/ -- Regado Biosciences, Inc., announced today the Company has completed enrollment in the Phase IIa clinical study of its REG1 Anticoagulation System in patients undergoing elective percutaneous coronary intervention (PCI). REG1 is a two-component system composed of an aptamer-based anticoagulant, RB006, and its matched, active reversal agent, RB007, which specifically binds to and neutralizes RB006. The Phase IIa study (REVERSAL-PCI) is designed to assess...

2008-10-14 09:00:11

FOR U.S. AUDIENCES ONLY The Medicines Company (NASDAQ:MDCO) -- today announced that 1-year clinical data from the HORIZONS-AMI trial, comparing Angiomax(R) (bivalirudin) vs. unfractionated heparin (UFH) plus glycoprotein IIb/IIIa Inhibitors (GPI), will be presented in a late-breaker presentation on October 15, 2008 in a session that begins at 11 am at the 2008 Transcatheter Cardiovascular Therapeutics (TCT) Conference, which is being held from Oct. 12 - Oct. 17, 2008, in Washington...

2008-10-08 21:00:27

Leg compression combined with medication such as heparin is more effective at preventing blood clots than either alone, U.S. researchers said. Deep vein thrombosis -- that causes severe leg swelling and ulcers -- can be fatal if the clot breaks free and travels to the lungs as a pulmonary embolism. By analyzing data from 11 trials involving 7,431 patients, Stavros Kakkos of the Henry Ford Hospital in Detroit found that a combined approach to prevention reduced the risk of deep vein...

2008-09-25 12:00:43

PolyMedix, a biotechnology company, has initiated dosing and commenced a Phase I clinical study in the US with its anticoagulant reversing agent PMX-60056 under an investigational new drug application filed with the FDA. This first Phase I clinical trial will assess the safety of PMX-60056. The protocol for this study involves a dose-escalation study in healthy volunteers in which each subject will receive a single dose of PMX-60056. The subjects are grouped into different cohorts with...

67ae2f2a21b86286aa8e0a14377898241
2008-09-24 13:15:00

The Joint Commission on Wednesday ordered new tougher restrictions on the use of blood thinners including heparin. The regulatory group said new measures may include bar-coding technology or computerized drug orders. Additionally, it called for tighter control on blood-thinning drugs and for hospitals to make sure that no adult-strength blood thinners were stored anywhere near children's units. The use of heparin has led to many mistakes and several deaths among patients. The commission...

2008-09-23 09:00:15

PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a Phase I clinical study in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA). PMX-60056 represents an entirely new class of drug,...

2008-09-10 03:00:05

The government yesterday began posting a list of prescription drugs under investigation for potential safety problems, in an effort to better inform doctors and patients. The first list is a bare-bones compilation naming 20 medications and the potential issue for each. It provides no indication of how widespread or serious the problems might be. This has led some consumer advocates to question its usefulness and prompted industry worries that skittish patients might stop taking a useful...

2008-09-03 12:00:33

The Medicines Company (NASDAQ:MDCO) today announced the presentation of a new analysis of data from the HORIZONS-AMI trial demonstrating that major bleeding contributes to more deaths at 30 days than repeat heart attack, or re-infarction, in severe heart attack patients treated with angioplasty. This analysis of ST-elevation myocardial infarction (STEMI) patients was presented at the European Society of Cardiology meeting in Munich, Germany. "The new analysis from HORIZONS-AMI reveals that...

2008-09-03 09:00:08

Japan-based pharmaceutical company Daiichi Sankyo Company has announced positive data from the clinical study of DU-176b, an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood. The data showed that DU-176b reduced the incidence of venous thromboembolism compared with dalteparin among patients undergoing elective unilateral hip replacement surgery. There was a statistically significant dose response in efficacy (P This randomized, double-blind comparative...

2008-09-02 09:00:07

MUNICH, Germany, Sept. 2 /PRNewswire/ -- Regado Biosciences, Inc. announced today the presentation of comprehensive results from Phase Ia, Ib and Ic studies of the Company's REG1 Anticoagulation System at the European Society of Cardiology's Congress 2008, currently being held in Munich, Germany. REG1 is a two-component system composed of an aptamer-based anticoagulant, RB006, and its matched, active reversal agent, RB007, which binds to and neutralizes RB006. Results from the three Phase...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related